IP Library › Patent Application 14124959
Patent Application
App. No. 14/124,959

Treatment of Respiratory Tract Illness with Bifidobacterium Lactis BL-04

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/124,959
Abstract

The present invention relates to a method of treating or prophlaxis of a respiratory tract illness in a subject comprising administering to said subject a composition comprising Bifidobacterium lactis BL04 and/or fermentation product of Bifidobacterium lactis BL04 and/or a cell lysate of Bifidobacterium lactis BL04.

Claims (36)

1 . A method of treating or prophlaxis of a respiratory tract illness in a subject comprising administering to said subject a composition comprising Bifidobacterium lactis BL04 and/or fermentation product of Bifidobacterium lactis BL04 and/or a cell lysate of Bifidobacterium lactis BL04.

2 . The method according to claim 1 , wherein the respiratory tract illness is an upper respiratory tract illness.

3 . The method according to claim 1 , wherein the respiratory tract illness is a lower respiratory tract illness.

4 . The method according to claim 1 , wherein the respiratory tract illness is selected from one or more of the group consisting of: tonsillitis, otitis media; rhinitis; rhinosinusitis, sinusitis; nasopharyngitis, rhinopharyngitis, the common cold; pharyngitis; epiglottitis; supraglottitis; laryngitis; laryngotracheitis; tracheitis; throat soreness, sneezing, blocked nose, runny nose and a cough.

5 . The method according to claim 1 wherein the respiratory tract illness is selected from one or more of the group consisting of: bronchitis, acute bronchitis, pneumonia and a lung abscess; coughing with chest congestion and coughing with wheezing.

6 . The method according to claim 1 , wherein granulocyte phagocytic activity and/or monocyte phagocytic activity in the subject is increased.

7 . The method according to claim 2 , wherein granulocyte phagocytic activity and/or monocyte phagocytic activity in the subject is increased.

8 . The method according to claim 3 , wherein granulocyte phagocytic activity and/or monocyte phagocytic activity in the subject is increased.

9 . The method according to claim 4 , wherein granulocyte phagocytic activity and/or monocyte phagocytic activity in the subject is increased.

10 . The method according to claim 5 , wherein granulocyte phagocytic activity and/or monocyte phagocytic activity in the subject is increased.

11 .

12 . The method according to claim 1 , wherein the method is prophylactic.

13 . The method according to claim 2 , wherein the method is prophylactic.

14 . The method according to claim 3 , wherein the method is prophylactic.

15 . The method according to claim 4 , wherein the method is prophylactic.

16 . The method according to claim 5 , wherein the method is prophylactic.

17 . The method according to claim 1 , wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10 8 to 10 12 CFU of Bifidobacterium lactis BL04/per day.

18 . The method according to claim 1 , wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10 8 to 10 12 CFU of Bifidobacterium lactis BL04/per day.

19 . The method according to claim 2 , wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10 8 to 10 12 CFU of Bifidobacterium lactis BL04/per day.

20 . The method according to claim 3 , wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10 8 to 10 12 CFU of Bifidobacterium lactis BL04/per day.

21 . The method according to claim 4 , wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10 8 to 10 12 CFU of Bifidobacterium lactis BL04/per day.

22 . The method according to claim 5 , wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10 8 to 10 12 CFU of Bifidobacterium lactis BL04/per day.

23 . The method according to claim 1 , comprising administering at least one further probiotic microorganism.

24 . The method according to claim 2 , comprising administering at least one further probiotic microorganism.

25 . The method according to claim 3 , comprising administering at least one further probiotic microorganism.

26 . The method according to claim 4 , comprising administering at least one further probiotic microorganism.

27 . The method according to claim 5 , comprising administering at least one further probiotic microorganism.

28 . The method according to claim 23 , wherein the at least one further probiotic microorganism is selected from the genera Lactobacillus, Streptococcus, Enterococcus, Bifidobacterium and Saccharomyces.

29 . The method according to claim 1 , wherein the composition is formulated a medicament, a food product or a dietary supplement.

30 . The method according to claim 2 , wherein the composition is formulated a medicament, a food product or a dietary supplement.

31 . The method according to claim 3 , wherein the composition is formulated a medicament, a food product or a dietary supplement.

32 . The method according to claim 4 , wherein the composition is formulated a medicament, a food product or a dietary supplement.

33 . The method according to claim 5 , wherein the composition is formulated a medicament, a food product or a dietary supplement.

34 . A method for modifying medication intake in a subject comprising administering an effective amount of a composition comprising Bifidobacterium lactis BL-04 and/or a fermentation product of Bifidobacterium lactis BL-04 and/or a cell lysate of Bifidobacterium lactis BL-04 to a subject.

35 . The method of claim 34 wherein the medication is cold or flu medication.

36 .